The cost-effectiveness of canagliflozin (CANA) versus sitagliptin (SITA) as third-line therapy in the treatment of type 2 diabetes mellitus (T2DM) in the UK

被引：0
|
作者：
Thompson, G. [1 ]
Schroeder, M. [1 ]
Neslusan, C. [2 ]
Willis, M. [3 ]
Johansen, P. [3 ]
Teschemaker, A. [2 ]
机构：
[1] Janssen UK, High Wycombe, Bucks, England
[2] Janssen Global Serv LLC, Raritan, NJ USA
[3] Swedish Inst Hlth Econ, Lund, Sweden
来源：
DIABETOLOGIA | 2014年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
817
引用
收藏
页码：S330 / S330
页数：1
相关论文
共 50 条
  • [1] IMPACT OF WEIGHT-RELATED UTILITIES ON THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) AS THIRD-LINE THERAPY IN TYPE 2 DIABETES MELLITUS (T2DM) IN A CANADIAN SETTING
    Sabapathy, S.
    Neslusan, C.
    Yoong, K.
    Teschemaker, A. R.
    Johansen, P.
    Willis, M.
    VALUE IN HEALTH, 2015, 18 (03) : A62 - A62
  • [2] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN VERSUS SITAGLIPTIN AS THIRD-LINE THERAPY IN TYPE 2 DIABETES MELLITUS (T2DM) IN A CANADIAN SETTING
    Sabapathy, S.
    Neslusan, C.
    Yoong, K.
    Teschemaker, A. R.
    Johansen, P.
    Willis, M.
    VALUE IN HEALTH, 2015, 18 (03) : A61 - A61
  • [3] COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) AS ADD-ON TO METFORMIN PLUS SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN BRAZIL
    Pititto, L.
    Neslusan, C.
    Teschemaker, A. R.
    Johansen, P.
    Willis, M.
    Asano, E.
    Puig, A.
    VALUE IN HEALTH, 2015, 18 (07) : A864 - A864
  • [4] The Cost-Effectiveness of Canagliflozin (CANA) vs. Sitagliptin as an Add-on to Metformin (MET) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the US
    Martin, Silas
    Neslusan, Cheryl
    Vo, Lien
    Teschemaker, Anna
    Johansen, Pierre
    Willis, Michael
    DIABETES, 2014, 63 : A310 - A310
  • [5] Time Until Insulin Initiation for Canagliflozin (CANA) vs. Sitagliptin (SITA) in Dual Therapy and Triple Therapy for Type 2 Diabetes Mellitus (T2DM) in the UK
    Schroeder, Melanie
    Chan, Edmond
    Willis, Michael
    Johansen, Pierre
    Nilsson, Andreas
    Schubert, Agata
    Neslusan, Cheryl
    DIABETES, 2016, 65 : A327 - A327
  • [6] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) AS AN AD-ON TO METFORMIN OR METFORMIN PLUS SULPHONYLUREA IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN SPAIN
    Nielsen, A. T.
    Pitcher, A.
    Lovato, E.
    Schubert, A.
    Hemels, M.
    Neslusan, C.
    Gonzalez, B.
    VALUE IN HEALTH, 2015, 18 (03) : A62 - A62
  • [7] ASSESSMENT OF THE KEY DRIVERS OF COST-EFFECTIVENESS IN THE ECONOMIC MODELLING OF CANAGLIFLOZIN (CANA) VERSUS GLIMEPIRIDE (GLIM) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN THE UK SETTING
    Thompson, G.
    Willis, M.
    Johansen, P.
    Neslusan, C.
    Schroeder, M.
    Girod, I
    VALUE IN HEALTH, 2013, 16 (07) : A441 - A441
  • [8] Canagliflozin (CANA) Compared With Sitagliptin (SITA) in Subjects With Type 2 Diabetes Mellitus (T2DM) on Metformin (MET) Over 52 Weeks
    Lavalle Gonzalez, Fernando J.
    Januszewicz, Andrzej
    Davidson, Jaime
    Qiu, Rose
    Tong, Cindy
    Meininger, Gary
    DIABETES, 2013, 62 : A61 - A61
  • [9] SOURCES OF LONG-TERM QUALITY ADJUSTED LIFE YEAR (QALY) GAINS FOR CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN THE UK SETTING
    Willis, M.
    Johansen, P.
    Schroeder, M.
    Thompson, G.
    Girod, I
    Neslusan, C.
    VALUE IN HEALTH, 2013, 16 (07) : A440 - A441
  • [10] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SAXAGLIPTIN (SAXA) AMONG OLDER INDIVIDUALS LIVING WITH TYPE 2 DIABETES MELLITUS (T2DM) IN CANADA
    Teschemaker, A. R.
    Neslusan, C.
    Sabapathy, S.
    Yoong, K.
    Johansen, P.
    Willis, M.
    VALUE IN HEALTH, 2015, 18 (03) : A62 - A63
12345